- Hoth Therapeutics' precision antisense candidate, **HT-KIT**, has shown positive findings from multiple preclinical programs, demonstrating compelling anti-tumor efficacy and a clean safety profile.  **[1711786_20250902NY62028:0]** 
- Preclinical models of gastrointestinal stromal tumors (GIST) and systemic mastocytosis showed **significant tumor cell death** within **24 hours** of HT-KIT treatment, with statistically significant tumor shrinkage observed by day 8.  **[1711786_20250902NY62028:0]** 
- In vitro, HT-KIT achieved **over 80% knockdown of KIT expression**, and multi-dose in vivo studies confirmed **no off-target toxicity** across critical organs.  **[1711786_20250902NY62028:0]** 
- GLP-validated bioanalytical results for HT-KIT, conducted by Altasciences Company, Inc., met or **exceeded strict bioanalytical benchmarks**, including 90.5% of Incurred Sample Reanalysis (ISR) values falling within ±30%, which is above the 66.7% regulatory minimum.  **[1711786_20250902NY62028:0]** 
- Hoth Therapeutics plans to integrate this bioanalytical data into its formal GLP toxicology package and is **preparing for an IND submission** and first-in-human trials for HT-KIT.  **[1711786_20250902NY62028:0]**

Hoth Therapeutics (HOTH)